During phase-II randomized, double-blind, and placebo-controlled clinical trials, an oral antiviral medication showed positive results against COVID-19 infection.
The antiviral drug Molnupiravir safely and efficiently clear the entire viral load in patients with symptomatic Coronavirus infection when taken in full dose within days.
Molnupiravir was first developed as a preventive medication and therapy for SARS and MERS in the early 2000s by American companies Ridgeback Biotherapeutics LP and Merck & Co. The drug has previously been shown to be effective against a variety of viruses that use an RNA-dependent RNA polymerase, which COVID-19 already has.
Molnupiravir was given to 202 non-hospitalized adults with confirmed COVID-19 infection and intermittent symptoms for more than a week in phase-II clinical trials.
Five days after acquiring Molnupiravir, 100 percent of the study group’s participants tested negative for Coronavirus, compared to just 24 percent of the placebo group’s participants.
Significant outcomes from phase-II clinical trials, according to experts, indicate that Molnupiravir can be a successful medication against Coronavirus. Because of its oral nature, it can also avoid serious symptoms and hospitalization. They say that if an oral-based treatment for COVID-19 had been available a year earlier, many lives might have been saved.